UK Achieves Global First Patient Recruitment in Novel COPD Treatment Trial
核心洞察
The NIHR Newcastle Commercial Research Delivery Centre (搜索) recruited the world's first patient to a major commercial study evaluating a novel treatment for chronic obstructive pulmonary disease (搜索) (COPD (搜索)).
The first participant was recruited within 103 days, significantly ahead of the UK government's target to reduce commercial trial setup times to under 150 days.
The study is investigating whether a new medicinal product can reduce airway inflammation (搜索), improve lung function, and prevent exacerbations by reducing mucus build-up in COPD (搜索) patients.
A team at the NIHR Newcastle Commercial Research Delivery Centre (搜索) (CRDC), based at the Royal Victoria Infirmary and hosted by The Newcastle upon Tyne Hospitals NHS Foundation Trust, has achieved a significant milestone by recruiting the first patient in the world to a major commercial study evaluating a novel treatment for chronic obstructive pulmonary disease (搜索) (COPD (搜索)).
This global first-patient-in achievement demonstrates the effectiveness of the partnership between the National Institute for Health and Care Research (NIHR (搜索)) and the Association of the British Pharmaceutical Industry (搜索) (ABPI (搜索)), which funds the CRDCs to accelerate commercial study setup and delivery across the UK.
Breakthrough Timeline and Performance
The Newcastle CRDC recruited the study's first participant within 103 days, significantly outpacing the government's national target to reduce commercial trial setup times to under 150 days. Being the first country to recruit a patient into a global trial serves as a critical marker for international sponsors when deciding where to place their most important studies.
Dr Maria Koufali, NIHR (搜索) Life Sciences Industry Director, emphasized the significance of this achievement: "The CRDCs are a cornerstone of the UK's new commercial research offer. As a network funded jointly by NIHR and ABPI (搜索), they provide a nationally coordinated, high-performance delivery platform that enables faster study setup, consistent delivery, and earlier access to innovation for patients. Today's global first-patient-in shows exactly what this investment was designed to achieve: world-class performance, stronger industry confidence and a more competitive UK that can attract the best commercial trials."
Novel COPD Treatment Under Investigation
COPD (搜索) is a common long-term lung condition that causes breathing difficulties and primarily affects middle-aged and older adults. Current treatments focus on managing symptoms and reducing inflammation. This study is investigating whether a new medicinal product can reduce airway inflammation (搜索), improve lung function, and prevent exacerbations by reducing mucus build-up.
Respiratory consultant Dr Nicholas Lane, who is leading the trial at the Newcastle Hospitals Trust, highlighted the clinical significance: "COPD (搜索) is a debilitating condition that affects every aspect of daily life. Research is essential to developing new treatments that can improve symptoms, prevent flare-ups and support better physical and mental health. We are proud to have offered the first participant globally the opportunity to join this important study and to contribute to research that could benefit people worldwide."
Streamlined Operational Excellence
The Newcastle CRDC achieved this milestone through innovative methods now being rolled out UK-wide via the NIHR (搜索) Industry Hub, which embeds a single national operating model for faster feasibility, setup and recruitment. Key strategies included:
- Conducting contracting and site-readiness processes in parallel with Health Research Authority (HRA) approvals
- Securing a signed contract within two weeks of HRA approval
- Rapid technical troubleshooting with the sponsor, including fast resolution of a spirometry calibration issue
- Close coordination between respiratory clinicians and CRDC delivery teams to line up eligible participants immediately upon green light to recruit
National Infrastructure Investment
In December 2024, a £71.8 million investment over seven years was awarded jointly from the NIHR (搜索) and the Voluntary Scheme for Branded Medicine Pricing, Access, and Growth (VPAG) Investment Programme to establish 20 CRDCs across the UK. Commencing in April, these new centres are designed to enhance the speed and efficiency of commercial clinical research delivery.
The CRDCs will work with industry and other research delivery infrastructure to support the UK's status as one of the best places in the world for innovative companies to conduct research by building further capacity in commercial contract research, providing dedicated staff and facilities, and making participation in research more accessible by supporting the decentralization of clinical trials to smaller district general hospitals and primary care settings.